These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
902 related articles for article (PubMed ID: 29334771)
1. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771 [TBL] [Abstract][Full Text] [Related]
2. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects. Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176 [TBL] [Abstract][Full Text] [Related]
3. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088 [TBL] [Abstract][Full Text] [Related]
4. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173 [TBL] [Abstract][Full Text] [Related]
5. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019 [TBL] [Abstract][Full Text] [Related]
6. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659 [TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241 [TBL] [Abstract][Full Text] [Related]
8. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071 [TBL] [Abstract][Full Text] [Related]
9. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. O'Hara M; Stashwick C; Haas AR; Tanyi JL Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126 [TBL] [Abstract][Full Text] [Related]
10. Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies. Zhang YC; Li XY; Deng Q; Ge YJ; Yi RR; Wang HJ; Wang JT; Zhou H; Kong XF; Liu RJ; Zhang YT; Li XP; He XW; Zhu HY Theranostics; 2024; 14(16):6249-6267. PubMed ID: 39431011 [No Abstract] [Full Text] [Related]
11. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Tarannum M; Dinh K; Vergara J; Birch G; Abdulhamid YZ; Kaplan IE; Ay O; Maia A; Beaver O; Sheffer M; Shapiro R; Ali AK; Dong H; Ham JD; Bobilev E; James S; Cameron AB; Nguyen QD; Ganapathy S; Chayawatto C; Koreth J; Paweletz CP; Gokhale PC; Barbie DA; Matulonis UA; Soiffer RJ; Ritz J; Porter RL; Chen J; Romee R Sci Adv; 2024 Jul; 10(28):eadn0881. PubMed ID: 38996027 [TBL] [Abstract][Full Text] [Related]
12. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682 [TBL] [Abstract][Full Text] [Related]
13. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461 [TBL] [Abstract][Full Text] [Related]
14. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289 [TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model. Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J Front Immunol; 2024; 15():1362904. PubMed ID: 38855110 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452 [TBL] [Abstract][Full Text] [Related]
18. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448 [TBL] [Abstract][Full Text] [Related]
20. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell. Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]